Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis

NCT07225361 is registered in ClinicalTrials.gov with Northwestern University as lead sponsor.

NCT NCT07225361
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07225361 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis
Lead sponsor
Northwestern University
Phase
Phase 4
Overall status
Recruiting
Start date
November 28, 2025
Completion date
August 1, 2029
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis, multiple sclerosis (ms) - relapsing-remitting